REGENERON PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, Amortization
REGENERON PHARMACEUTICALS, INC. (REGN) reported Finance Lease, Right-of-Use Asset, Amortization of $14.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $3.60M.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $3.60M.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $3.70M.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $3.50M.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $14.50M, a 0.00% change from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $14.50M, a 0.00% change from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $14.50M, a 0.00% change from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $14.50M, a 0.69% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $14.50M 10-K · filed 2026-02-04 | |||
| 2024-12-31 | $14.50M 10-K · filed 2026-02-04 | |||
| 2023-12-31 | $14.50M 10-K · filed 2026-02-04 | |||
| 2022-12-31 | $14.50M 10-K · filed 2025-02-05 | |||
| 2021-12-31 | $14.40M 10-K · filed 2024-02-05 | |||
| 2020-12-31 | $14.40M 10-K · filed 2022-02-07 | |||
| 2019-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $7.20M derived: sum of 2 quarters · filed 2021-02-08 | $10.90M derived: sum of 3 quarters · filed 2021-02-08 | $14.40M 10-K · filed 2021-02-08 |
| 2019-09-30 | $3.60M 10-Q · filed 2019-11-05 | $7.30M derived: sum of 2 quarters · filed 2019-11-05 | $10.80M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $3.70M 10-Q · filed 2019-08-06 | $7.20M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $3.50M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |